Advanced Drug Delivery Systems: New Developments, New Technologies

Home
Medical Equipment and Supplies
Pharmaceuticals
Advanced Drug Delivery Systems: New Developments, New Technologies

Advanced Drug Delivery Systems: New Developments, New Technologies

Price:

USD $4,850.00

ISBN/SKU #:

GB-PHM006G

Research Group:

BCC

Date of Publication:

August 2009

Summary

This study is to provide an overview of the current and potential aspects of the global market for advanced drug delivery systems and its future direction, with an emphasis on newer techniques and products. The report determines the market size and market leaders, provides a market overview, and examines factors affecting the markets for drug delivery systems, including the use of these products in therapeutic markets.

An overview of types of drug delivery systems is also examined along with sales figures over the 5 year period from 2009 to 2014. This study provides an overview of the drug delivery market, which will grow at a compound annual growth rate (CAGR) of 7.2% over the forecast period 2009 through 2014.

The study presents market size and future trends, profiles market leaders, and analyzes factors affecting drug delivery markets and important products. The report also examines future trends in drug delivery technology, the basic principles underlying different systems, and their applications. Companies manufacturing and selling the drug delivery products are also profiled. Revenues have been broken down by the type of drug delivery systems and by different regions.

Our key objective is to present a comprehensive analysis of the current market and the future direction of the advanced drug delivery systems.

The drug delivery market is changing drastically due to the introduction of new techniques and routes of delivery. R&D spending, along with increasing competition, patent expiries, new technologies, an international marketplace, and a changing customer base, is creating a new kind of market for drug delivery systems. This study looks at almost all the systems affected by these factors.

This is a very complex market, where many technologies are combined together to produce a better delivery system, thus creating niche markets with very specialized applications. The use of liposomes, polymers, etc. in the sustained-release oral/injectable drug delivery market is a good example. Prodrugs, PEGylation, nanoparticles, and liposomes are significant new markets.

Acquisition strategies and collaborations by companies are also covered in this report, for example, the acquisition of the Pulmonary Division of Nektar Therapeutics by Novartis. This study also discusses the strength and weaknesses of drug development market in light of the new technologies, growing competition, and changing customer needs.

The report consolidates much of the information on new products and new technologies in the drug delivery industry. The study contributes to understanding market growth and decline in drug delivery market from the point of view of the manufacturer and user. This study will be of interest to manufacturers and end-users in the pharmaceutical and biotechnology industries, and to companies involved in R&D for drug delivery systems and new drugs.

This study encompasses the major types of drug delivery systems used in the health industry and analyzes each technology and looks at the manufacturers, their new products, sales estimates, market projections, and some market share information. This study also analyzes the industry on a worldwide basis. Patents for drug delivery technologies are also studied by year, country, and assignee. The Food and Drug Administration (FDA) approvals for the past 5 years have been covered. New developments in this field have been examined in detail, including those that comprise a part of individual company profiles.

Report Highlights:

The global market for advanced drug delivery systems amounted to $134.3 billion in 2008, and was projected to increase to $139 billion in 2009. The estimate for 2014 is $196.4 billion, for a compound annual growth rate (CAGR) of 7.2% in the 5-year period.
The largest segment of the market is targeted drug delivery, which reached $50.9 billion in 2009 and is expected to increase to $80.2 billion in 2014, for a CAGR of 9.5%.
Sustained-release products have the second-largest market share, with estimated sales of $36.1 billion in 2009 and $45.8 billion in 2014, for a CAGR of 4.9%.

TABLE OF CONTENTS

Chapter- 1: INTRODUCTION -- Complimentary

STUDY OBJECTIVES

REASONS FOR DOING THIS STUDY

INTENDED AUDIENCE

SCOPE OF THE STUDY

METHODOLOGY

INFORMATION SOURCES

ABOUT THE AUTHOR

RELATED BCC REPORTS

BCC ONLINE SERVICES

DISCLAIMER

Chapter-2: SUMMARY

SUMMARY

SUMMARY TABLE GLOBAL SALES FOR DRUG DELIVERY PRODUCTS, THROUGH 2014 ($ BILLIONS)

SUMMARY FIGURE GLOBAL SALES FOR DRUG DELIVERY PRODUCTS, 2007-2014 ($ BILLIONS)

Chapter-3: OVERVIEW

DEFINITIONS

NEED FOR THE DOSAGE FORMS

CLASSIFICATION OF DOSAGE FORMS ACCORDING TO PHYSICAL PROPERTIES

GASEOUS DOSAGE FORMS

TABLE 1 GASEOUS DOSAGE FORMS, ADVANTAGES AND DISADVANTAGES

LIQUID DOSAGE FORMS

TABLE 2 LIQUID DOSAGE FORMS, ADVANTAGES AND DISADVANTAGES

SEMISOLID DOSAGE FORMS

TABLE 3 SEMISOLID DOSAGE FORMS, ADVANTAGES AND DISADVANTAGES

SOLID DOSAGE FORMS

TABLE 4 SOLID DOSAGE FORMS, ADVANTAGES AND DISADVANTAGES

CLASSIFICATION OF DRUG DELIVERY ACCORDING TO ROUTE OF ADMINISTRATION

TOPICAL DRUG DELIVERY

TABLE 5 TOPICAL DRUG DELIVERY, ADVANTAGES AND DISADVANTAGES

ORAL DRUG DELIVERY

TABLE 6 ORAL DRUG DELIVERY, ADVANTAGES AND DISADVANTAGES

INJECTABLE OR PARENTERAL DRUG DELIVERY

TABLE 7 INJECTABLE OR PARENTERAL DRUG DELIVERY, ADVANTAGES AND DISADVANTAGES

RECTAL DRUG DELIVERY

TABLE 8 RECTAL DRUG DELIVERY, ADVANTAGES AND DISADVANTAGES

NASAL DRUG DELIVERY

TABLE 9 NASAL DRUG DELIVERY, ADVANTAGES AND DISADVANTAGES

TABLE 9 (CONTINUED)

VAGINAL DRUG DELIVERY

TABLE 10 VAGINAL DRUG DELIVERY, ADVANTAGES AND DISADVANTAGES

OCULAR DRUG DELIVERY

TABLE 11 OCULAR DRUG DELIVERY, ADVANTAGES AND DISADVANTAGES

PULMONARY DRUG DELIVERY

TABLE 12 PULMONARY DRUG DELIVERY, ADVANTAGES AND DISADVANTAGES

CLASSIFICATION OF DRUG DELIVERY BASED ON TECHNOLOGY

SUSTAINED-RELEASE DRUG DELIVERY

TABLE 13 SUSTAINED-RELEASE DELIVERY, ADVANTAGES AND DISADVANTAGES

DELAYED-RELEASE DRUG DELIVERY

TABLE 14 DELAYED-RELEASE DELIVERY, ADVANTAGES AND DISADVANTAGES

PRODRUGS

TABLE 15 PRODRUGS, ADVANTAGES AND DISADVANTAGES

IMPLANTS AND IUDS

TABLE 16 IMPLANTS AND IUDS, ADVANTAGES AND DISADVANTAGES

TARGETED DRUG DELIVERY

Nanoparticles

Liposomes

TABLE 17 LIPOSOMES, ADVANTAGES AND DISADVANTAGES

Polymers

TABLE 18 POLYMERS, ADVANTAGES AND DISADVANTAGES

Monoclonal Antibodies

TABLE 19 MONOCLONAL ANTIBODIES, ADVANTAGES AND DISADVANTAGES

PEGylation

TABLE 20 PEGYLATION, ADVANTAGES AND DISADVANTAGES

Chapter-4: REGULATORY ISSUES

TABLE 21 FDA-APPROVED DRUGS OF VARIOUS DOSAGE FORMS (2005 TO FEB 2009)

TABLE 22 NUMBER OF NEW APPROVALS FOR DRUG DELIVERY PRODUCTS IN EACH YEAR, 2005- FEB. 2009

FIGURE 1 NUMBER OF NEW APPROVALS FOR DRUG DELIVERY PRODUCTS IN EACH YEAR, 2005 TO FEB. 2009

TABLE 23 APPROVED DRUGS OF VARIOUS DOSAGE FORMS, THROUGH OTHER AGENCIES (2005 TO FEB 2009)

TABLE 24 RECALLS/ SAFETY ALERTS FOR DRUG DELIVERY SYSTEMS (2005 TO FEB. 2009)

Chapter-5: CLASSIFICATION OF DRUG PRODUCTS BASED ON DRUG DELIVERY TYPE

SUSTAINED-RELEASE ORAL DOSAGE FORMS

TABLE 25 MAJOR SUPPLIERS AND MANUFACTURERS OF SUSTAINED-RELEASE ORAL DOSAGE FORMS

SUSTAINED-RELEASE INJECTABLE DOSAGE FORMS

TABLE 26 MAJOR SUPPLIERS AND MANUFACTURERS OF SUSTAINED-RELEASE INJECTABLE DOSAGE FORMS

SUSTAINED-RELEASE TOPICAL DOSAGE FORMS

TABLE 27 MAJOR SUPPLIERS AND MANUFACTURERS OF SUSTAINED-RELEASE TOPICAL DOSAGE FORMS

PRODRUGS

TABLE 28 MAJOR SUPPLIERS AND MANUFACTURERS OF PRODRUGS

IMPLANTS AND IUDS

TABLE 29 MAJOR SUPPLIERS AND MANUFACTURERS OF IMPLANTS AND IUDS

TRANSDERMAL DRUG DELIVERY SYSTEMS

TABLE 30 MAJOR SUPPLIERS AND MANUFACTURERS OF TRANSDERMAL DRUG DELIVERY SYSTEMS

LIPOSOMES

TABLE 31 MAJOR SUPPLIERS AND MANUFACTURERS OF LIPOSOMES

NANOPARTICLES

TABLE 32 MAJOR SUPPLIERS AND MANUFACTURERS OF NANOPARTICLES

POLYMERS

TABLE 33 MAJOR SUPPLIERS AND MANUFACTURERS OF POLYMERS

MONOCLONAL ANTIBODIES

TABLE 34 MAJOR SUPPLIERS AND MANUFACTURERS OF MONOCLONAL ANTIBODIES

PEGYNOLOGY

TABLE 35 MAJOR SUPPLIERS AND MANUFACTURERS OF PEGNOLOGY

BUCCAL DRUG DELIVERY SYSTEMS

TABLE 36 MAJOR SUPPLIERS AND MANUFACTURERS OF BUCCAL DRUG DELIVERY SYSTEMS

RECTAL DRUG DELIVERY SYSTEMS

TABLE 37 MAJOR SUPPLIERS AND MANUFACTURERS OF RECTAL DRUG DELIVERY SYSTEMS

VAGINAL DRUG DELIVERY SYSTEMS

TABLE 38 MAJOR SUPPLIERS AND MANUFACTURERS OF VAGINAL DRUG DELIVERY SYSTEMS

OCULAR DRUG DELIVERY SYSTEMS

TABLE 39 MAJOR SUPPLIERS AND MANUFACTURERS OF OCULAR DRUG DELIVERY SYSTEMS

INHALATION SYSTEMS

TABLE 40 MAJOR SUPPLIERS AND MANUFACTURERS OF INHALTION SYSTEMS

Chapter-6: INDUSTRY STRUCTURE

SUSTAINED-RELEASE DOSAGE FORMS

SUSTAINED-RELEASE ORAL DOSAGE FORM

TABLE 41 SHARES OF MANUFACTURERS/SUPPLIERS FOR SUSTAINED-RELEASE ORAL DOSAGE FORMS, 2008 (%)

FIGURE 2 SHARES OF MANUFACTURERS/SUPPLIERS OF SUSTAINED-RELEASE ORAL DOSAGE FORMS, 2008 (%)

SUSTAINED-RELEASE INJECTABLE DOSAGE FORM

TABLE 42 SHARES OF MANUFACTURERS/SUPPLIERS FOR SUSTAINED-RELEASE INJECTABLE DOSAGE FORMS, 2008 (%)

FIGURE 3 SHARES OF MANUFACTURERS/SUPPLIERS OF SUSTAINED-RELEASE INJECTABLE DOSAGE FORMS, 2008 (%)

SUSTAINED-RELEASE TOPICAL DOSAGE FORM

TABLE 43 SHARES OF MANUFACTURERS/SUPPLIERS FOR SUSTAINED-RELEASE TOPICAL DOSAGE FORMS, 2008 (%)

FIGURE 4 SHARES OF MANUFACTURERS/SUPPLIERS OF SUSTAINED-RELEASE TOPICAL DOSAGE FORMS, 2008 (%)

PRODRUGS

TABLE 44 SHARES OF MANUFACTURERS/SUPPLIERS FOR PRODRUGS, 2008 (%)

FIGURE 5 SHARES OF MANUFACTURERS/SUPPLIERS OF PRODRUGS, 2008 (%)

IMPLANTS AND IUDS

TABLE 45 SHARES OF MANUFACTURERS FOR IMPLANTS AND IUDS, 2008 (%)

FIGURE 6 SHARES OF MANUFACTURERS OF IMPLANTS AND IUDS, 2008 (%)

TRANSDERMAL DRUG DELIVERY SYSTEMS

TABLE 46 SHARES OF MANUFACTURERS/SUPPLIERS FOR TRANSDERMAL DRUG DELIVERY SYSTEMS, 2008 (%)

FIGURE 7 SHARES OF MANUFACTURERS/SUPPLIERS OF TRANSDERMAL DRUG DELIVERY SYSTEMS, 2008 (%)

TARGETED DRUG DELIVERY SYSTEMS

LIPOSOMES

TABLE 47 SHARES OF MANUFACTURERS/SUPPLIERS FOR LIPOSOMES, 2008 (%)

FIGURE 8 SHARES OF MANUFACTURERS/SUPPLIERS OF LIPOSOMES, 2008 (%)

NANOPARTICLES

TABLE 48 SHARES OF MANUFACTURERS/SUPPLIERS FOR NANOPARTICLES, 2008 (%)

FIGURE 9 SHARES OF MANUFACTURERS/SUPPLIERS OF NANOPARTICLES, 2008 (%)

POLYMERS

TABLE 49 SHARES OF MANUFACTURERS/SUPPLIERS FOR POLYMERS, 2008 (%)

FIGURE 10 SHARES OF MANUFACTURERS/SUPPLIERS OF POLYMERS, 2008 (%)

MONOCLONAL ANTIBODIES

TABLE 50 SHARES OF MANUFACTURERS/SUPPLIERS FOR MONOCLONAL ANTIBODIES, 2008 (%)

FIGURE 11 SHARES OF MANUFACTURERS/SUPPLIERS OF MONOCLONAL ANTIBODIES, 2008 (%)

PEGNOLOGY

TABLE 51 SHARES OF MANUFACTURERS/SUPPLIERS FOR PEGNOLOGY, 2008 (%)

FIGURE 12 SHARES OF MANUFACTURERS/SUPPLIERS OF PEGNOLOGY, 2008 (%)

TRANSMUCOSAL DRUG DELIVERY SYSTEMS

BUCCAL DRUG DELIVERY SYSTEMS

TABLE 52 SHARES OF MANUFACTURERS/SUPPLIERS FOR BUCCAL DRUG DELIVERY SYSTEMS, 2008 (%)

FIGURE 13 SHARES OF MANUFACTURERS/ SUPPLIERS OF BUCCAL DRUG DELIVERY SYSTEMS, 2008 (%)

RECTAL DRUG DELIVERY SYSTEMS

TABLE 53 SHARES OF MANUFACTURERS/SUPPLIERS FOR RECTAL DRUG DELIVERY SYSTEMS, 2008 (%)

FIGURE 14 SHARES OF MANUFACTURERS/ SUPPLIERS OF RECTAL DRUG DELIVERY SYSTEMS, 2008 (%)

VAGINAL DRUG DELIVERY SYSTEMS

TABLE 54 SHARES OF MANUFACTURERS/SUPPLIERS FOR VAGINAL DRUG DELIVERY SYSTEMS, 2008 (%)

FIGURE 15 SHARES OF MANUFACTURERS/ SUPPLIERS OF VAGINAL DRUG DELIVERY SYSTEMS, 2008 (%)

OCULAR DRUG DELIVERY SYSTEMS

TABLE 55 SHARES OF MANUFACTURERS/SUPPLIERS FOR OCULAR DRUG DELIVERY SYSTEMS, 2008 (%)

FIGURE 16 SHARES OF MANUFACTURERS/SUPPLIERS OF OCULAR DRUG DELIVERY SYSTEMS, 2008 (%)

INHALATION SYSTEMS

TABLE 56 SHARES OF MANUFACTURERS/SUPPLIERS OF INHALATION SYSTEMS, 2008 (%)

FIGURE 17 SHARES OF MANUFACTURERS/SUPPLIERS OF INHALATION SYSTEMS, 2008 (%)

Chapter-7: DEMAND AND USE

OVERALL DRUG DELIVERY MARKET

FACTORS AFFECTING THE DRUG DELIVERY TECHNOLOGY MARKET

PATENT EXPIRATION

TABLE 57 DRUGS WHICH LOST THEIR PATENTS IN 2008

TABLE 58 DRUGS WHICH WILL LOSE THEIR PATENTS IN 2009

DEMAND FOR NEW DRUG DELIVERY TECHNOLOGIES

POOR EFFICACY OF CERTAIN DRUGS

COMPETITION

CHALLENGES FOR DRUG DELIVERY COMPANIES

DEMANDS AND TRENDS

Chapter-8: MARKET ANALYSIS

TABLE 59 GLOBAL SALES OF DRUG DELIVERY PRODUCTS, THROUGH 2014 ($ BILLIONS)

FIGURE 18 GLOBAL SALES OF DRUG DELIVERY SYSTEMS, 2007-2014 ($ BILLIONS)

TABLE 60 MARKET SHARE OF DRUG DELIVERY PRODUCTS, 2008 (%)

FIGURE 19 MARKET SHARE OF DRUG DELIVERY SYSTEM, 2008 (%)

SUSTAINED-RELEASE ORAL DOSAGE FORMS

MARKET SIZE

TABLE 61 GLOBAL SALES OF SUSTAINED-RELEASE ORAL DOSAGE FORMS, THROUGH 2014 ($ MILLIONS)

FIGURE 20 TOTAL GLOBAL SALES OF SUSTAINED-RELEASE ORAL DOSAGE FORMS, 2007-2014 ($ MILLIONS)

MARKET OVERVIEW

SUSTAINED-RELEASE INJECTABLE DOSGAE FORM

MARKET SIZE

TABLE 62 GLOBAL SALES OF SUSTAINED-RELEASE INJECTABLE DOSAGE FORMS, THROUGH 2014 ($ MILLIONS)

FIGURE 21 TOTAL GLOBAL SALES OF SUSTAINED-RELEASE INJECTABLE DOSAGE FORMS, 2007-2014 ($ MILLIONS)

MARKET OVERVIEW

SUSTAINED-RELEASE TOPICAL DOSAGE FORMS

MARKET SIZE

TABLE 63 GLOBAL SALES OF SUSTAINED-RELEASE TOPICAL DOSAGE FORMS, THROUGH 2014 ($ MILLIONS)

FIGURE 22 TOTAL GLOBAL SALES OF SUSTAINED-RELEASE TOPICAL DOSAGE FORMS, 2007-2014 ($ MILLIONS)

MARKET OVERVIEW

PRODRUGS

MARKET SIZE

TABLE 64 TOTAL GLOBAL SALES OF PRODRUGS, THROUGH 2014 ($ MILLIONS)

FIGURE 23 GLOBAL SALES OF PRODRUGS, 2007-2014 ($ MILLIONS)

MARKET OVERVIEW

IMPLANTS AND IUDS

MARKET SIZE

TABLE 65 GLOBAL SALES OF IMPLANTS AND IUDS, THROUGH 2014 ($ MILLIONS)

FIGURE 24 TOTAL GLOBAL SALES OF IMPLANTS AND IUDS, 2007-2014 ($ MILLIONS)

MARKET OVERVIEW

TRANSDERMAL DRUG DELIVERY

MARKET SIZE

TABLE 66 GLOBAL SALES OF TRANSDERMAL DRUG DELIVERY SYSTEMS, THROUGH 2014 ($ MILLIONS)

FIGURE 25 TOTAL GLOBAL SALES OF TRANSDERMAL DRUG DELIVERY SYSTEMS, 2007-2014 ($ MILLIONS)

MARKET OVERVIEW

LIPOSOMES DRUG DELIVERY

MARKET SIZE

TABLE 67 GLOBAL SALES OF LIPOSOMES, THROUGH 2014 ($ MILLIONS)

FIGURE 26 TOTAL GLOBAL SALES OF LIPOSOMES, 2007-2014 ($ MILLIONS)

MARKET OVERVIEW

NANOPARTICLES

MARKET SIZE

TABLE 68 GLOBAL SALES OF NANOPARTICLES, THROUGH 2014 ($ MILLIONS)

FIGURE 27 GLOBAL SALES OF NANOPARTICLES, 2007-2014 ($ MILLIONS)

MARKET OVERVIEW

POLYMERS

MARKET SIZE

TABLE 69 GLOBAL SALES OF POLYMERS, THROUGH 2014 ($ MILLIONS)

FIGURE 28 GLOBAL SALES OF POLYMERS, 2007-2014 ($ MILLIONS)

MARKET OVERVIEW

PEGYLATED DRUG DELIVERY

MARKET SIZE

TABLE 70 GLOBAL SALES OF PEGYLATED DRUG DELIVERY, THROUGH 2014 ($ MILLIONS)

FIGURE 29 TOTAL GLOBAL SALES OF PEGYLATED DRUG DELIVERY, 2007-2014 ($ MILLIONS)

MARKET OVERVIEW

MONOCLONAL ANTIBODIES

MARKET SIZE

TABLE 71 GLOBAL SALES OF MONOCLONAL ANTIBODIES, THROUGH 2014 ($ MILLIONS)

FIGURE 30 TOTAL GLOBAL SALES OF MONOCLONAL ANTIBODIES, 2007-2014 ($ MILLIONS)

MARKET OVERVIEW

BUCCAL DRUG DELIVERY

MARKET SIZE

TABLE 72 GLOBAL SALES OF BUCCAL DRUG DELIVERY, THOUGH 2014 ($ MILLIONS)

FIGURE 31 TOTAL GLOBAL SALES OF BUCCAL DRUG DELIVERY, 2007-2014 ($ MILLIONS)

MARKET OVERVIEW

RECTAL DRUG DELIVERY

MARKET SIZE

TABLE 73 GLOBAL SALES OF RECTAL DRUG DELIVERY, THROUGH 2014 ($ MILLIONS)

FIGURE 32 TOTAL GLOBAL SALES OF RECTAL DRUG DELIVERY, 2007-2014 ($ MILLIONS)

MARKET OVERVIEW

OCULAR DRUG DELIVERY

MARKET SIZE

TABLE 74 GLOBAL SALES OF OCULAR DRUG DELIVERY, THROUGH 2014 ($ MILLIONS)

FIGURE 33 TOTAL GLOBAL SALES OF OCULAR DRUG DELIVERY, 2007-2014 ($ MILLIONS)

MARKET OVERVIEW

VAGINAL DRUG DELIVERY

MARKET SIZE

TABLE 75 GLOBAL SALES OF VAGINAL DRUG DELIVERY, THROUGH 2014 ($ MILLIONS)

FIGURE 34 TOTAL GLOBAL SALES OF VAGINAL DRUG DELIVERY, 2007-2014 ($ MILLIONS)

MARKET OVERVIEW

INHALATION DRUG DELIVERY

MARKET SIZE

TABLE 76 GLOBAL SALES OF INHALATION DRUG DELIVERY, THROUGH 2014 ($ MILLIONS)

FIGURE 35 TOTAL GLOBAL SALES OF INHALATION DRUG DELIVERY, 2007-2014 ($ MILLIONS)

MARKET OVERVIEW

Chapter-9: NEW DEVELOPMENTS

TABLE 77 DEVELOPMENTS IN SUSTAINED-RELEASE ORAL DOSAGE FORMS

TABLE 78 DEVELOPMENTS IN SUSTAINED-RELEASE INJECTABLE DOSAGE FORMS

TABLE 79 DEVELOPMENTS IN SUSTAINED-RELEASE TOPICAL DOSAGE FORMS

TABLE 80 DEVELOPMENTS IN PRODRUGS

TABLE 81 DEVELOPMENTS IN IMPLANTS AND IUDS

TABLE 82 DEVELOPMENTS IN TRANSDERMAL DRUG DELIVERY SYSTEMS

TABLE 83 DEVELOPMENTS IN LIPOSOMAL DELIVERY

TABLE 84 DEVELOPMENTS IN PEGYLATED DRUG DELIVERY

TABLE 85 DEVELOPMENTS IN NANOPARTICLE DRUG DELIVERY

TABLE 86 DEVELOPMENTS IN MONOCLONAL ANTIBODIES

TABLE 87 DEVELOPMENTS IN BUCCAL DRUG DELIVERY

TABLE 88 DEVELOPMENTS IN VAGINAL DRUG DELIVERY

TABLE 89 DEVELOPMENTS IN RECTAL DRUG DELIVERY

TABLE 90 DEVELOPMENTS IN INHALATION DRUG DELIVERY

Chapter-10: MARKET BY THERAPEUTIC AREAS

MARKET SIZE

TABLE 91 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN EACH THERAPEUTIC AREA, THROUGH 2014 ($ BILLIONS)

FIGURE 36 GLOBAL SALES OF DRUGS TO TREAT LIVER DISEASES, 2007-014 ($ BILLIONS)

MARKET SHARE

TABLE 92 SHARE OF DRUG DELIVERY SYSTEMS IN THERAPEUTIC AREAS, 2008 (%)

FIGURE 37 SHARE OF DRUG DELIVERY SYSTEMS IN THERAPEUTIC AREAS, 2008 (%)

CARDIOVASCULAR DISEASES

MARKET SIZE

TABLE 93 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN CARDIOVASCULAR DISEASES, THROUGH 2004 ($ BILLIONS)

FIGURE 38 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN CARDIOVASCULAR DISEASES, 2007-2014 ($ BILLIONS)

ONCOLOGY

MARKET SIZE

TABLE 94 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN ONCOLOGY, THROUGH 2014 ($ BILLIONS)

FIGURE 39 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN ONCOLOGY, 2007-2014 ($ BILLIONS)

GASTROINTESTINAL

MARKET SIZE

TABLE 95 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN GASTROINTESTINAL DISORDERS, THROUGH 2014 ($ BILLIONS)

FIGURE 40 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN GASTROINTESTINAL DISORDERS, 2007-2014 ($ BILLIONS)

UROLOGY

MARKET SIZE

TABLE 96 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN UROLOGY, THROUGH 2014 ($ BILLIONS)

FIGURE 41 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN UROLOGY, 2007-2014 ($ BILLIONS)

DIABETES

MARKET SIZE

TABLE 97 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN DIABETIC MARKET, THROUGH 2014 ($ BILLIONS)

FIGURE 42 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN DIABETIC MARKET, 2007-2014 ($ BILLIONS)

CENTRAL NERVOUS SYSTEM DISORDER

MARKET SIZE

TABLE 98 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN CENTERAL NERVOUS SYSTEM MARKET, THROUGH 2014 ($ BILLIONS)

FIGURE 42 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN CENTRAL NERVOUS SYSTEM MARKET, 2007-2014 ($ BILLIONS)

RESPIRATORY DRUG DELIVERY SYSTEMS

MARKET SIZE

TABLE 99 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN RESPIRATORY DISEASES, THROUGH 2014 ($ BILLIONS)

FIGURE 44 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN RISPIRATORY DISEASES, 2007-2014 ($ BILLIONS)

INFLAMMATORY DISEASES AND ALLERGY

MARKET SIZE

TABLE 100 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN INFLAMMATORY AND ALLERGY, 2007-2014 ($ BILLIONS)

FIGURE 45 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN INFLAMMATORY AND ALLERGY DISEASES, 2007-2014 ($ BILLIONS)

OPHTHALMOLOGY

MARKET SIZE

TABLE 101 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN OPHTHALMOLOGY, THROUGH 2014 ($ BILLIONS)

FIGURE 46 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN OPHTHALMOLOGY, 2007-2014 ($ BILLIONS)

VIRAL AND BACTERIAL DISEASES

MARKET SIZE

TABLE 102 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN VIRAL AND BACTERIAL DISEASES, THROUGH 2014 ($ BILLIONS)

FIGURE 47 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN VIRAL AND BACTERIAL DISEASES, 2007-2014 ($ BILLIONS)

HORMONE REPLACEMENT THERAPY (HRT) AND GYNECOLOGY

MARKET SIZE

TABLE 103 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN HORMONE REPLACEMENT THERAPY AND GYNECOLOGY, THROUGH 2014 ($ BILLIONS)

FIGURE 48 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN HORMONE REPLACEMENT THERAPY AND GYNECOLOGY, 2007-2014 ($ BILLIONS)

OTHERS

MARKET SIZE

TABLE 104 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN OTHER THERAPEUTIC AREAS AND TECHNOLOGIES, THROUGH 2014 ($ BILLIONS)

FIGURE 49 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN OTHER THERAPEUTIC AREAS AND TECHNOLOGIES, 2007-2014 ($ BILLIONS)

Chapter-11: PATENT ANALYSIS

PATENTS BY YEAR

TABLE 105 TOTAL NUMBER OF PATENTS IN EACH YEAR, 2005-2009

FIGURE 50 NUMBER OF PATENTS, 2005-2009

PATENTS BY TYPE

TABLE 106 NUMBER OF PATENTS BY TYPE, 2005-2009

FIGURE 51 NUMBER OF PATENTS BY TYPE, 2005-2009

FIGURE 52 TOTAL NUMBER OF PATENTS, SHARE BY TYPE, 2005-2009 (%)

PATENTS BY COUNTRY

TABLE 107 TOTAL NUMBER OF PATENTS BY COUNTRY, 2005-2009

FIGURE 53 TOTAL NUMBER OF PATENTS BY COUNTRY, 2005-2009

PATENTS BY COMPANY

TABLE 108 NUMBER OF PATENTS BY COMPANY, 2005-2009

FIGURE 54 NUMBER OF PATENTS BY COMPANY, 2005-2009

PATENTS BY ASSIGNEE

TABLE 109 NUMBER OF PATENTS BY ASSIGNEE, 2005-2009

FIGURE 55 NUMBER OF PATENTS BY ASSIGNEE, 2005-2009

Chapter-12: COMPANY PROFILES

ABBOTT LABORATORIES

ABRAXIS BIOSCIENCE, INC.

AKELA PHARMA

AKORN, INC.

ALCON, INC.

ALEXION PHARMACEUTICALS

ALKERMES, INC.

ALLERGAN

ALPHARX

AMGEN

ANTIGENICS

A P PHARMA

ASTELLAS PHARMA

ASTRAZENECA

ATON PHARMA

BARR PHARMACEUTICALS, INC.

BAXTER

BAYER HEALTHCARE

BIOGEN IDEC

BIOSANTE PHARMACEUTICALS, INC.

BIOVAIL

BOEHRINGER INGELHEIM

BRISTOL MYERS SQUIBB

CENTOCOR

CEPHALON INC.

COLUMBIA LABS

DIATOS SA

EISAI CO.

ELAN

ENZON

EURAND N.V.

GENENTECH

GENEREX BIOTECH

GENZYME

GILEAD SCIENCES, INC.

GLAXOSMITHKLINE PLC

IMCLONE SYSTEMS

JOHNSON AND JOHNSON

KING PHARMACEUTICALS

K.V. PHARMACEUTICAL CO.

LAVIPHARM CORPORATION

3M COMPANY

MERCK & CO.

MYLAN LABORATORIES, INC.

NEKTAR THERAPEUTICS

NOVEN PHARMACEUTICALS, INC.

NOVARTIS AG

NOVAVAX, INC.

NYCOMED US, INC.

OSI PHARMACEUTICALS, INC.

PAR PHARMACEUTICAL COMPANIES, INC.

PDL BIOPHARMA, INC.

PFIZER INC.

QLT, INC.

ROCHE

SANOFI-AVENTIS

SCHERING-PLOUGH

TEVA PHARMACEUTICAL INDUSTRIES, LTD.

WATSON PHARMACEUTICALS, INC.

WYETH, INC.

APPENDIX: ABBREVIATIONS

ABBREVIATIONS

Warranty Information

Number of Pages: 176

New Publications